All In Biotech

Drug Trial Radar · NCT05524571

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

86

Actual

Start

Jan 5, 2023

Primary completion

Feb 3, 2026

Study completion Mar 3, 2026

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Sep 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

Conditions

  • Thyroid Eye Disease

Interventions

  • BatoclimabDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of proptosis respondersTime frame: At Week 24

Locations

45 sites in 11 countries. Site status is shown where the registry gives one.

  • Site Number -1520

    Pasadena, California

  • Site Number -1517

    San Francisco, California

  • Site Number -1514

    Torrance, California

  • Site Number -1510

    Sarasota, Florida

  • Site Number -1516

    Louisville, Kentucky

  • Site Number - 1526

    Livonia, Michigan

  • Site Number - 1513

    Rochester, Minnesota

  • Site Number - 1512

    Winston-Salem, North Carolina

  • Site Number - 1525

    Portland, Oregon

  • Site Number -1515

    Bellaire, Texas

  • Site Number - 1524

    McAllen, Texas

  • Site Number -1519

    San Antonio, Texas

  • Site Number - 1521

    Seattle, Washington

  • Site Number -1511

    Morgantown, West Virginia

  • Site Number - 1518

    Milwaukee, Wisconsin

  • Site Number - 7565

    Sydney, Australia

  • Site Number -4671

    Bruges, Belgium

  • Site Number - 4672

    Brussels, Belgium

  • Site Number - 4673

    Brussels, Belgium

  • Site Number -4670

    Ghent, Belgium

  • Site Number - 4674

    Liège, Belgium

  • Site Number - 6603

    Mainz, Rhineland-Palatinate, Germany

  • Site Number - 7550

    Budapest, Hungary

  • Site Number - 7551

    Pécs, Hungary

  • Site Number - 7552

    Pécs, Hungary

  • Site Number -9301

    Ogre, Latvia

  • Site Number -9300

    Riga, Latvia

  • Site Number - 9302

    Ventspils, Latvia

  • Site Number - 7570

    Christchurch, New Zealand

  • Site Number - 7572

    Hamilton, New Zealand

  • Site Number -1990

    San Juan, Puerto Rico

  • Site Number - 9203

    Bratislava, Slovakia

  • Site Number - 9200

    Bratislava, Slovakia

  • Site Number - 9201

    Bratislava, Slovakia

  • Site Number - 9202

    Trenčín, Slovakia

  • Site Number -3602

    Barcelona, Spain

  • Site Number - 3605

    Barcelona, Spain

  • Site Number -3601

    Madrid, Spain

  • Site Number -3604

    Madrid, Spain

  • Site Number -3600

    Santiago de Compostela, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.